Abstract
A new series of thiazolidine derivatives with an adamantyl group was synthesized and evaluated for their ability to inhibit 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1). Our initial compound 5a showed a weak inhibitory activity. Significant improvements in potency were achieved by substituent modification. The potent compound 8g (E) showed good in vitro inhibitory activity toward human 11β-HSD1, selectivity toward 11β-HSD2, metabolic stability, pharmacokinetic, and safety profile. Furthermore, this compound significantly inhibited 11β-HSD1 activity in rat and monkey models, and showed improved glycemic control in KKAy mice.
Original language | English |
---|---|
Pages (from-to) | 435-439 |
Number of pages | 5 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 21 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2011 Jan 1 |
Bibliographical note
Funding Information:This research was supported by the Center for Biological Modulators of the 21st Century Frontier R&D Program, the Ministry of Education, Science and Technology, and the Ministry of Knowledge Economy, Korea.
Keywords
- 11beta-HSD1
- Adamantyl
- Diabetes
- Thiazolidine
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Pharmaceutical Science
- Drug Discovery
- Clinical Biochemistry
- Organic Chemistry